Kozak & Associates’s Vertex Pharmaceuticals VRTX Stock Holding History

Kozak & Associates’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.47K	Hold	13	–	–	﹤0.01%	292
2026 Q1	$5.72K	Hold	13	–	–	﹤0.01%	298
2025 Q4	$6.03K	Hold	13	–	–	﹤0.01%	295
2025 Q3	$5.64K	Hold	13	–	–	﹤0.01%	300
2025 Q2	$6.23K	Hold	13	–	–	﹤0.01%	274
2025 Q1	$6.45K	Hold	13	–	–	﹤0.01%	259
2024 Q4	$5.29K	Hold	13	–	–	﹤0.01%	290
2024 Q3	$6.33K	Hold	13	–	–	﹤0.01%	261
2024 Q2	$6.11K	Hold	13	–	–	﹤0.01%	257
2024 Q1	$5.73K	Hold	13	–	–	﹤0.01%	268
2023 Q4	$5.69K	Hold	13	–	–	﹤0.01%	267
2023 Q3	$4.69K	Hold	13	–	–	﹤0.01%	290
2023 Q2	$4.52K	Hold	13	–	–	﹤0.01%	278
2023 Q1	$4.1K	Hold	13	–	–	﹤0.01%	278
2022 Q4	$4K	Hold	13	–	–	﹤0.01%	280
2022 Q3	$4K	Hold	13	–	–	﹤0.01%	277
2022 Q2	$4K	Hold	13	–	–	﹤0.01%	312
2022 Q1	$3K	Hold	13	–	–	﹤0.01%	345
2021 Q4	$3K	Hold	13	–	–	﹤0.01%	345
2021 Q3	$2K	Buy	+13	New	+$2.54K	﹤0.01%	312

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

CTB

Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

GIA

Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return

MLL

Moody Lynn & Lieberson Boston, Massachusetts $1.9B AUM 27.82% 1-Year Est. Return

Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

Kozak & Associates's VRTX Position: Q2 2026 in Review

Kozak & Associates held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 13 shares worth $6.47K. The position accounts for ﹤0.01% of the portfolio, ranked #292.

Kozak & Associates first reported a position in VRTX in Q3 2021 and has held it in 20 quarters since. 296 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Kozak & Associates held 13 shares of Vertex Pharmaceuticals worth $6.47K as of Q2 2026.
Kozak & Associates left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
Vertex Pharmaceuticals made up ﹤0.01% of Kozak & Associates's portfolio in Q2 2026, its #292 holding.
Kozak & Associates first reported a position in Vertex Pharmaceuticals in Q3 2021 and has held it in 20 quarters since.
296 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Kozak & Associates's 13F filing for Q2 2026, filed 2 Jul 2026.